| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/21/2007 | WO2007068395A1 Diphenyl urea derivatives |
| 06/21/2007 | WO2007068383A1 Diaryl ureas for treating virus infections |
| 06/21/2007 | WO2007068382A1 Diaryl urea for treating inflammatory skin. eye and/or ear diseases |
| 06/21/2007 | WO2007068381A1 Diaryl ureas for treating inflammatory skin, eye and/or ear diseases |
| 06/21/2007 | WO2007068380A1 Diaryl urea for treating virus infections |
| 06/21/2007 | WO2007068372A1 Method for finishing textiles with care oils |
| 06/21/2007 | WO2007068330A1 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS |
| 06/21/2007 | WO2007068316A1 Hydroxyquinoline derivatives |
| 06/21/2007 | WO2007068212A1 Intravenous emulsion of butylbenzene phthalein and its application |
| 06/21/2007 | WO2007068188A1 Camptothecin compounds with a substituent located in 10-position comprising multi-carboxyl groups, their preparation processes and their pharmaceutical compositions |
| 06/21/2007 | WO2007068171A1 CRYSTALLINE FORM I OF 3,4',5-TRIHYDROXY-STIBENE-3-β-D-GLUCOSIDE |
| 06/21/2007 | WO2007068116A1 Method for correcting a lipid imbalance in a subject |
| 06/21/2007 | WO2007068115A1 Method of detecting and reducing boar taint using nuclear receptors |
| 06/21/2007 | WO2007068113A1 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof |
| 06/21/2007 | WO2007068112A1 Method of treating pain by using opioids and camkiv inhibitors |
| 06/21/2007 | WO2007068084A1 Novel macrolide compounds with antibiotic and antneoplastic properties |
| 06/21/2007 | WO2007068076A1 Chitin derivatives for hyperlipidemia |
| 06/21/2007 | WO2007068073A2 Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine |
| 06/21/2007 | WO2007068070A2 Composition containing an inhibitor of phosphodiesterase iii and a therapeutic alcohol for the treatment of atherosclerosis diseases |
| 06/21/2007 | WO2007068055A1 A method for preventing reduced feed intake in animals and treatment of disease conditions |
| 06/21/2007 | WO2007053514A3 Chemical preconditioning as a preventative or treatment for excitotoxic synaptic damage |
| 06/21/2007 | WO2007051062A3 Substituted dihydropyridines and methods of use |
| 06/21/2007 | WO2007050697A3 Compositions and methods for the administration psychotropic drugs which modulate body weight |
| 06/21/2007 | WO2007050564A3 Boron-containing porphyrin compounds and their uses |
| 06/21/2007 | WO2007050353A3 Tricyclic compounds useful as oxytocin receptor agonists |
| 06/21/2007 | WO2007048064A3 Amino-pyrimidines as casein kinase ii (ck2) modulators |
| 06/21/2007 | WO2007047893A3 Use of dasatinib for the treatment of bone metastasis |
| 06/21/2007 | WO2007047447A3 Diuretic-like compound analogs useful for regulation of central nervous system disorders |
| 06/21/2007 | WO2007045462A3 Novel vanilloid receptor ligands and their use for producing medicaments |
| 06/21/2007 | WO2007042544A3 Imidazole derivatives and their use for modulating the gabaa receptor complex |
| 06/21/2007 | WO2007042543A3 Imidazole derivatives and their use for modulating the gaba-a receptor complex |
| 06/21/2007 | WO2007039821A3 Novel inhibitors of tyrosinase, their method of preparation and their use in human medicine and in cosmetics |
| 06/21/2007 | WO2007039635A3 Phosphoantigen salts of organic bases and methods for their crystallization |
| 06/21/2007 | WO2007039462A3 Indane derivatives as mch receptor antagonists |
| 06/21/2007 | WO2007039075A3 Pde inhibitors and combinations thereof for the treatment of urological disorders |
| 06/21/2007 | WO2007038720A3 Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| 06/21/2007 | WO2007035355A3 Modulators of metabolism and the treatment of disorders related thereto |
| 06/21/2007 | WO2007033307A3 Inhibition of intermediate-conductance calcium activated potassium channels in the treatment and/or prevention of atherosclerosis |
| 06/21/2007 | WO2007031621B1 Metronidazole-based dermatological foam and emulsions for the production thereof |
| 06/21/2007 | WO2007031620B1 Metronidazole-based dermatological foam and emulsions for the production thereof |
| 06/21/2007 | WO2007030567A3 Pparactive compounds |
| 06/21/2007 | WO2007029121A3 Novel cyclopent-2-en-1-one derivatives which are ppar receptor modulators, and use thereof in pharmaceutical or cosmetic compositions |
| 06/21/2007 | WO2007028512A3 Magnetic-field controlled active substance transfer for aerosol therapy |
| 06/21/2007 | WO2007028012A3 Antibacterial 6'-n-modified 4,5-substituted aminoglycoside analogs |
| 06/21/2007 | WO2007022380A3 Bis-aryl amide compounds and methods of use |
| 06/21/2007 | WO2007021629A3 Non-nucleoside reverse transcriptase inhibitors |
| 06/21/2007 | WO2007019131A3 Use of lipid conjugates in cystic fibrosis and applications thereof |
| 06/21/2007 | WO2007017893B1 Preparation of novel crystalline form of perindopril erbumine monohydrate |
| 06/21/2007 | WO2007016087A3 Heterocyclic benzodiazepine cgrp receptor antagonists |
| 06/21/2007 | WO2007015757A3 Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
| 06/21/2007 | WO2007014392A3 Benzoquinones of enhanced bioavailability |
| 06/21/2007 | WO2007011880A3 Enhanced ocular neuroprotection/neurostimulation |
| 06/21/2007 | WO2007011619A3 Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate |
| 06/21/2007 | WO2007009801A3 Oral, quickly disintegrating film, which cannot be spit out, for a neuroleptic drug |
| 06/21/2007 | WO2007008652A3 Methods and compositions directed to dj-1 as regulator of the anti-oxidant transcription factor nrf2 |
| 06/21/2007 | WO2007007327A3 Il-32 modulators |
| 06/21/2007 | WO2007005763A3 Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer |
| 06/21/2007 | WO2007003604A3 Hists1mine h3 receptor antagonists |
| 06/21/2007 | WO2007002831A3 Topical skin treating compostions |
| 06/21/2007 | WO2007001466A3 Peptidomimetic somatostatin receptor subtype 2 ligands and pet imaging agents |
| 06/21/2007 | WO2007001282A3 Low molecular weight polyglucosamines and polygalactosamines |
| 06/21/2007 | WO2006133931A3 Identification of jak/stat pathway modulating genes by genome wide rnai screening |
| 06/21/2007 | WO2006133261A3 Organic compounds |
| 06/21/2007 | WO2006131649A3 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones |
| 06/21/2007 | WO2006130666A3 Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| 06/21/2007 | WO2006130426A3 Modulators of ccr-5 activity |
| 06/21/2007 | WO2006129204A3 Rnai for control of insects and arachnids |
| 06/21/2007 | WO2006127592A8 Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts |
| 06/21/2007 | WO2006124861A3 Benzofuran compounds |
| 06/21/2007 | WO2006123257A8 Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1, 2 , 4]0xadiaz0l-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
| 06/21/2007 | WO2006115918A3 Vla-4 antagonists |
| 06/21/2007 | WO2006099942A3 Use of amino-substituted benzimidazoles |
| 06/21/2007 | WO2006099359A3 Methods of reducing microbial contamination |
| 06/21/2007 | WO2006091587A3 Use of minoxidil sulfate as an anti-tumor drug |
| 06/21/2007 | WO2006083440A3 Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
| 06/21/2007 | WO2006078369A3 Methods and compositions for treatment of viral infections |
| 06/21/2007 | WO2006073457A8 Bioactive compounds and methods of uses thereof |
| 06/21/2007 | WO2006065724A3 Casein kinase 2 antisense therapy |
| 06/21/2007 | WO2006063168A3 Oxytocin receptor antagonists and their use for the treatment of pulmonary related diseases |
| 06/21/2007 | WO2006056047A9 Cathepsin cysteine protease inhibitors |
| 06/21/2007 | WO2006010041A3 Morpholino antisense drugs for human herpesvirus 8 |
| 06/21/2007 | WO2006002348A8 Solid and crystalline ibandronic acid |
| 06/21/2007 | WO2005084655A8 1-aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease |
| 06/21/2007 | WO2005046318A3 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| 06/21/2007 | WO2005037223A3 Methods and compositions for immunomodulation |
| 06/21/2007 | WO2002100330A9 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES |
| 06/21/2007 | US20070143871 Non-human transgenic animal models for hepatocellular carcinoma |
| 06/21/2007 | US20070142718 Noninvasive measurement of chemical substances |
| 06/21/2007 | US20070142681 Process for chlorinating tertiary alcohols |
| 06/21/2007 | US20070142670 e.g., N-(1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-N-methyl-N-(1-phenylethyl)amine; intermediates for medicines and agricultural chemicals |
| 06/21/2007 | US20070142647 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues |
| 06/21/2007 | US20070142640 Method for producing 1, 2-dihydropyridine-2-one compound |
| 06/21/2007 | US20070142634 phenylamide and pyridylamide derivative compounds having a terminal or branched amino or hydroxyl group |
| 06/21/2007 | US20070142539 Octahydronaphtalene derivative and medicine |
| 06/21/2007 | US20070142480 Alleviation of pain in osteoarthritis by means of intra-articular implantation of perfluorodecalin. |
| 06/21/2007 | US20070142479 Free base in crystalline form, purity; deprotecting while preventing dimer impurity formation; claimed phenolic intermediates |
| 06/21/2007 | US20070142478 Combination antimicrobial composition and method of use |
| 06/21/2007 | US20070142477 Analgesia |
| 06/21/2007 | US20070142476 Biphenyl-Derivatives as p38 Kinase Inhibitors |
| 06/21/2007 | US20070142475 Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors |